Forest Laboratories acquiring Clinical Data Inc. for $30 per share in cash valued at about $928.6M, plus a contingent value right of up to $6 based on sales milestones of Viibryd vilazodone

Clinical Data Inc.

U.S. / Medical Devices and Diagnostics

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Forest Laboratories Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Completed

Sample

01/01/2009

announced

01/01/2009

completed